Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali ® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...
Diagnostic criteria for pulmonary fibrosis and other fibrotic diseases in children are lacking. That void hampers an ...
“We need global awareness of lipoprotein (a),” Tremulis tells Fortune. “High lipoprotein (a) impacts one in five globally…And ...
Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty ...
The Powder Keg podcast investigates complaints of liver harm from users of a market-leading nutraceutical created by a NZ ...
FDA approval streamlines Acetadote dosing, enhancing safety and efficiency in treating acetaminophen-related liver injury in ...
Under the agreements, AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 ...
Kidney stones, those painful crystalline formations in your urinary system, might soon be defeated by an innovative medical ...
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a Tennessee-based specialty pharmaceutical company, saw its stock price surge by a remarkable 95.96% to $2.43 in Tuesday’s premarket trading session.
Galderma should launch its skin drug Nemluvio, to treat prurigo nodularis in the U.S. and Europe; Ipsen will bring its rare liver disease drug Iqirvo to market; and Sandoz is set to introduce a ...
Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...